In this Microsoft SQL Server and JDBC tutorial, you'll learn how to connect to a Microsoft SQL Server in Java using JDBC. The steps are relatively straightforward: Each database is different, so ...

The goal of a machine learning binary classification problem is to predict a variable that has exactly two possible values. For example, you might want to predict the sex of a company employee (male = ...

Google is reportedly using AI to rewrite some news headlines in Search, and early results indicate the system isn’t fully ready yet. As spotted by The Verge, Google is modifying some of the outlet’s ...

Abstract: Narrow passage scenarios pose significant challenges for path planning, especially for tasks requiring real-time performance. Traditional asymptotically converging sampling-based planners ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...